In 2019, the company received FDA-approval for Vyleesi (bremelanotide acetate), an injectable -MSH analogue, making it the first FDA-approved melanocortin agent 15, 47
A bias factor ( ), which quantifies the relative engagement of one signalling state over another compared with the reference peptide, was calculated using the following equation: Where E max is the maximal effect, EC 50 is the half maximal concentration of the peptide, lig is the peptide being tested (P5 or GLP-1)
Dietary supplements containing Tribulus extracts are purported to be useful for enhancing athletic performance
No surgical recovery time
Bioavailability of 80-95% provides efficient peptide utilization
Cigna added that another factor in its MLR performance was higher-than-expected stop-loss costs, according to the earnings report